- Viking Therapeutics plans $200M common stock offering
Viking Therapeutics plans to offer $200 million of common stock and $200 million of convertible senior notes due 2032. Underwriters have 30-day options to buy up to an additional $30 million of each. Proceeds will fund clinical development of VK2735 and VK3019 programs and general corporate purposes. Shares fell 8.2% to $38.24 in after-hours trading.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.